Skip to main content

Deal Dive: Cutting through the noise in a category clouded by catastrophic failure

Building a startup is hard enough but growing one in a category marred with Theranos-sized stigma is a new level of challenge. Vital Bio seems up for the test.

The Toronto-based startup is building a machine, VitalOne, that can perform more than 50 blood tests — covering nearly all of those considered routine — and get patient results back in 20 minutes, not multiple days. Co-founder and CEO Vasu Nadella said that he got interested in the space because he and his co-founders have watched family members deal with chronic illness and know that being able to get quick diagnostic results is crucial for treatment.

Plus, Nadella wanted to know why companies couldn’t seem to get the solution to this problem right. While Theranos failed for a variety of reasons, the other companies trying to build these quicker blood diagnostic tools had yet to ship products. He thought maybe he could crack the code.

The startup launched in 2019 and built quietly until it debuted its device at the American Association of Clinical Chemistry’s annual meeting — the industry’s “Super Bowl” — last Monday. Vital Bio also announced that it had raised $48 million in venture funding from Labcorp, Inovia Capital, Lachy Groom and Sam Altman, among others.

Nadella said the company has focused on making sure that its device produces accurate results and that when it does drift, they know how to prevent it from impacting the final diagnosis. He said the company waited to start talking about what it was up to until it felt it had enough to back up its claims.



source https://techcrunch.com/2023/07/29/vital-bio-blood-testing-theranos/

Comments

Popular posts from this blog

Max Q: Psyche(d)

In this issue: SpaceX launches NASA asteroid mission, news from Relativity Space and more. © 2023 TechCrunch. All rights reserved. For personal use only. from TechCrunch https://ift.tt/h6Kjrde via IFTTT

Max Q: Anomalous

Hello and welcome back to Max Q! Last week wasn’t the most successful for spaceflight missions. We’ll get into that a bit more below. In this issue: First up, a botched launch from Virgin Orbit… …followed by one from ABL Space Systems News from Rocket Lab, World View and more Virgin Orbit’s botched launch highlights shaky financial future After Virgin Orbit’s launch failure last Monday, during which the mission experienced an  “anomaly” that prevented the rocket from reaching orbit, I went back over the company’s financials — and things aren’t looking good. For Virgin Orbit, this year has likely been completely turned on its head. The company was aiming for three launches this year, but everything will remain grounded until the cause of the anomaly has been identified and resolved. It’s unclear how long that will take, but likely at least three months. Add this delay to Virgin’s dwindling cash reserves and you have a foundation that’s suddenly much shakier than before. ...

What’s Stripe’s deal?

Welcome to  The Interchange ! If you received this in your inbox, thank you for signing up and your vote of confidence. If you’re reading this as a post on our site, sign up  here  so you can receive it directly in the future. Every week, I’ll take a look at the hottest fintech news of the previous week. This will include everything from funding rounds to trends to an analysis of a particular space to hot takes on a particular company or phenomenon. There’s a lot of fintech news out there and it’s my job to stay on top of it — and make sense of it — so you can stay in the know. —  Mary Ann Stripe eyes exit, reportedly tried raising at a lower valuation The big news in fintech this week revolved around payments giant Stripe . On January 26, my Equity Podcast co-host and overall amazingly talented reporter Natasha Mascarenhas and I teamed up to write about how Stripe had set a 12-month deadline for itself to go public, either through a direct listing or by pursuin...